| Modelling the tumour microenvironment in long-term microencapsulated 3D co-cultures recapitulates phenotypic features of disease progression MF Estrada, SP Rebelo, EJ Davies, MT Pinto, H Pereira, VE Santo, ... Biomaterials 78, 50-61, 2016 | 130 | 2016 |
| Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices EJ Davies, M Dong, M Gutekunst, K Närhi, HJAA Van Zoggel, S Blom, ... Scientific reports 5 (1), 17187, 2015 | 127 | 2015 |
| Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors MJ Sale, E Minihane, NR Monks, R Gilley, FM Richards, KP Schifferli, ... Nature communications 10 (1), 5167, 2019 | 63 | 2019 |
| PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine EJ Davies, V Marsh Durban, V Meniel, GT Williams, AR Clarke The Journal of pathology 233 (1), 27-38, 2014 | 56 | 2014 |
| Structure-guided discovery of potent and selective inhibitors of ERK1/2 from a modestly active and promiscuous chemical start point RA Ward, P Bethel, C Cook, E Davies, JE Debreczeni, G Fairley, L Feron, ... Journal of medicinal chemistry 60 (8), 3438-3450, 2017 | 54 | 2017 |
| Discovery of a potent and selective oral inhibitor of ERK1/2 (AZD0364) that is efficacious in both monotherapy and combination therapy in models of nonsmall cell lung cancer … RA Ward, MJ Anderton, P Bethel, J Breed, C Cook, EJ Davies, A Dobson, ... Journal of medicinal chemistry 62 (24), 11004-11018, 2019 | 48 | 2019 |
| PTEN loss and KRAS activation cooperate in murine biliary tract malignancies V Marsh, EJ Davies, GT Williams, AR Clarke The Journal of pathology 230 (2), 165-173, 2013 | 48 | 2013 |
| Protocols and characterization data for 2D, 3D, and slice-based tumor models from the PREDECT project R De Hoogt, MF Estrada, S Vidic, EJ Davies, A Osswald, M Barbier, ... Scientific data 4 (1), 1-23, 2017 | 47 | 2017 |
| Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery A Lundin, MJ Porritt, H Jaiswal, F Seeliger, C Johansson, AW Bidar, ... Nature communications 11 (1), 4903, 2020 | 44 | 2020 |
| Origin and maintenance of the intestinal cancer stem cell EJ Davies, V Marsh, AR Clarke Molecular carcinogenesis 50 (4), 254-263, 2011 | 40 | 2011 |
| Epithelial-specific loss of PTEN results in colorectal juvenile polyp formation and invasive cancer VM Durban, M Jansen, EJ Davies, FH Morsink, GJA Offerhaus, AR Clarke The American Journal of Pathology 184 (1), 86-91, 2014 | 28 | 2014 |
| Selumetinib-based therapy in uveal melanoma patient-derived xenografts D Decaudin, R El Botty, B Diallo, G Massonnet, J Fleury, A Naguez, ... Oncotarget 9 (31), 21674, 2018 | 27 | 2018 |
| AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor … V Flemington, EJ Davies, D Robinson, LC Sandin, O Delpuech, P Zhang, ... Molecular cancer therapeutics 20 (2), 238-249, 2021 | 15 | 2021 |
| A microfluidic system that replicates pharmacokinetic (PK) profiles in vitro improves prediction of in vivo efficacy in preclinical models D Singh, SP Deosarkar, E Cadogan, V Flemington, A Bray, J Zhang, ... Plos Biology 20 (5), e3001624, 2022 | 8 | 2022 |
| Multiscalar cellular automaton simulates in-vivo tumour-stroma patterns calibrated from in-vitro assay data JA Delgado-SanMartin, JI Hare, EJ Davies, JWT Yates BMC medical informatics and decision making 17, 1-12, 2017 | 3 | 2017 |
| Generation and characterisation of an estrogen receptor-positive GEMM-derived Pten p53 null transplantable breast tumour model for therapeutic testing EJ Davies, H Morgan, G Tornillo, CD Chabbert, H Kendrick, ... bioRxiv, 762047, 2019 | 1 | 2019 |
| Abstract B156: Discovery and characterization of AZ6197, a potent and selective ERK1/2 inhibitor V Flemington, I Simpson, E Davies, D Robinson, N Lindsay, L Hanson, ... Molecular Cancer Therapeutics 17 (1_Supplement), B156-B156, 2018 | 1 | 2018 |
| The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma B Diallo, G Massonnet, R El-Botty, C Raymondie, G Carita, ... Cancer Research 76 (14_Supplement), 2087-2087, 2016 | 1 | 2016 |
| Mimicking disease progression features by modulation of the tumour microenvironment in stirred-tank culture systems MF Estrada, SP Rebelo, VE Santo, EJ Davies, S Abreu, MT Pinto, ... European Journal of Cancer 1 (61), S74, 2016 | | 2016 |
| 145 Tumour-stromal architecture influences prognosis and response to docetaxel in prostate cancer S Bokobza, K Hiew, R Huby, E Davies, M Brown, S Barry, B Davies, ... European Urology Supplements 3 (15), e145, 2016 | | 2016 |
Alan R Clarkecardiff universityVerified email at cf.ac.uk
Alan R Clarkecardiff universityVerified email at cf.ac.uk